Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Middle or Lower Thoracic Esophageal Squamous Cell Carcinoma
Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Listed as NCT02123381, this PHASE2 trial focuses on Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma and remains ongoing. Sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University, it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Apr 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Apr 2022 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jun 2018 — Apr 2020 [monthly]
Unknown Status PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Sichuan Cancer Hospital and Research Institute
- Southwest Hospital, China
- Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .